Anonymous
Guest
Anonymous
Guest
hearing a lot of hype around solaneuzumab from Lilly and bapineuzumab from J&J/Pfizer. are either of these drugs actually going to come to market, and are we back to me too's now with such similar compounds?
Dr. P. Murali Doraiswamy, a Duke University professor of biological psychiatry and advisor to the Alzheimer's Foundation of America, said success for solanezumab would be a landmark achievement.
"I personally think the chances are almost zero," he said, noting that so many previous drugs have failed because they tried to treat people who already showed symptoms of Alzheimer's.
If it doesn't work then what does that say about our new imaging drug? We just hired a new sales force to sell it- I thought the belief was the imaging drug was going to be a blockbuster? Supposedly we have only hired the best of the best to rep it??? I know the west coast manager (SB) is known as an up and comer in the organization and was hand picked to start the sales force from scratch!
Maybe it will have a placebo effect. A good sales force can still sell it.
The fact is, the malformed tau protein now appears to be the culprit. All amyloid bets appear to be off.
Time for your research managers to drop the six sigma and go back to school. On their time and expense.
So Lilly scientists have been "barking up the wrong tree" ???
But we have a $16.5 Million PhD CEO with over 40 years with Lilly....